“Hemolysis, or not Hemolysis, that is the question”. Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency. Hemolysis by Hemolysis and G6PD deficiency.
Main Article Content
Keywords
Downloads
Download data is not yet available.
Abstract 911
PDF Downloads 678
HTML Downloads 207
References
Costanzo M, De Giglio MAR, Roviello GN. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus. Curr Med Chem. 2020;27(27):4536-4541. https://doi.org/10.2174/0929867327666200416131117 PMid:32297571
2. ISS COVID-19 Rare Diseases Working Group. Interim guidance for the appropriate support of people with enzymopenia G6PD (favism) in the current SARS-CoV-2 emergency scenario. Version April 14, 2020. Roma: Istituto Superiore di Sanità; 2020. (Rapporto ISS COVID-19, n. 14/2020 - English version).
3. Beauverd Y, Adam Y, Assouline B, Samii K. COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency [published online ahead of print, 2020 Apr 23]. Eur J Haematol. 2020;10.1111/ejh.13432. https://doi.org/10.1111/ejh.13432 PMid:32324284 PMCid:PMC7264743
4. Maillart E, Leemans S, Van Noten H, et al. A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine. Infect Dis (Lond). 2020;52(9):659-661.
https://doi.org/10.1080/23744235.2020.1774644 PMid:32496938 PMCid:PMC7284136
5. Sasi S, Yassin MA, Nair AP, Al Maslamani MS. A Case of COVID-19 in a Patient with Asymptomatic Hemoglobin D Thalassemia and Glucose-6-Phosphate Dehydrogenase Deficiency. Am J Case Rep. 2020;21:e925788. Published 2020 Jul 22.
https://doi.org/10.12659/AJCR.925788 PMid:32697769 PMCid:PMC7394553
6. De Franceschi L, Costa E, Dima F, Morandi M, Olivieri O. Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with severe COVD-19 related lung injury. Eur J Intern Med. 2020;77:136-137. https://doi.org/10.1016/j.ejim.2020.04.020 PMid:32381323 PMCid:PMC7167571
7. Roper D, Layton M, Rees D, et al. Laboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline. Br J Haematol. 2020;189(1):24-38.https://doi.org/10.1111/bjh.16366; PMid:31991476
8. Pietrapertosa A, Palma A, Campanale D, Delios G, Vitucci A, Tannoia N. Genotype and phenotype correlation in glucose-6-phosphate dehydrogenase deficiency. Haematologica. 2001;86(1):30-35.
9. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64-74.
https://doi.org/10.1016/S0140-6736(08)60073-2
10. Kassi EN, Papavassiliou KA, Papavassiliou AG. G6PD and chloroquine: Selecting the treatment against SARS-CoV-2?. J Cell Mol Med. 2020;24(9):4913-4914. https://doi.org/10.1111/jcmm.15312 PMid:32281268 PMCid:PMC7205832
2. ISS COVID-19 Rare Diseases Working Group. Interim guidance for the appropriate support of people with enzymopenia G6PD (favism) in the current SARS-CoV-2 emergency scenario. Version April 14, 2020. Roma: Istituto Superiore di Sanità; 2020. (Rapporto ISS COVID-19, n. 14/2020 - English version).
3. Beauverd Y, Adam Y, Assouline B, Samii K. COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency [published online ahead of print, 2020 Apr 23]. Eur J Haematol. 2020;10.1111/ejh.13432. https://doi.org/10.1111/ejh.13432 PMid:32324284 PMCid:PMC7264743
4. Maillart E, Leemans S, Van Noten H, et al. A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine. Infect Dis (Lond). 2020;52(9):659-661.
https://doi.org/10.1080/23744235.2020.1774644 PMid:32496938 PMCid:PMC7284136
5. Sasi S, Yassin MA, Nair AP, Al Maslamani MS. A Case of COVID-19 in a Patient with Asymptomatic Hemoglobin D Thalassemia and Glucose-6-Phosphate Dehydrogenase Deficiency. Am J Case Rep. 2020;21:e925788. Published 2020 Jul 22.
https://doi.org/10.12659/AJCR.925788 PMid:32697769 PMCid:PMC7394553
6. De Franceschi L, Costa E, Dima F, Morandi M, Olivieri O. Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with severe COVD-19 related lung injury. Eur J Intern Med. 2020;77:136-137. https://doi.org/10.1016/j.ejim.2020.04.020 PMid:32381323 PMCid:PMC7167571
7. Roper D, Layton M, Rees D, et al. Laboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline. Br J Haematol. 2020;189(1):24-38.https://doi.org/10.1111/bjh.16366; PMid:31991476
8. Pietrapertosa A, Palma A, Campanale D, Delios G, Vitucci A, Tannoia N. Genotype and phenotype correlation in glucose-6-phosphate dehydrogenase deficiency. Haematologica. 2001;86(1):30-35.
9. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64-74.
https://doi.org/10.1016/S0140-6736(08)60073-2
10. Kassi EN, Papavassiliou KA, Papavassiliou AG. G6PD and chloroquine: Selecting the treatment against SARS-CoV-2?. J Cell Mol Med. 2020;24(9):4913-4914. https://doi.org/10.1111/jcmm.15312 PMid:32281268 PMCid:PMC7205832
Article Sidebar
Published
Oct 27, 2020
Article Details
How to Cite
SGHERZA, N. (2020) “‘Hemolysis, or not Hemolysis, that is the question’. Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency.: Hemolysis by Hemolysis and G6PD deficiency”., Mediterranean Journal of Hematology and Infectious Diseases, 12(1), p. e2020076. doi: 10.4084/mjhid.2020.076.
Issue
Section
Letters to the Editor
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.